(DeLeon Maria C) - Indiana University School of Medicine Departments of Obstetrics and Gynecology
(Ammakkanavar Natraj R) - Indiana University School of Medicine Department of Biochemistry and Molecular Biology,
(Matei Daniela) - Indiana University School of Medicine Departments of Obstetrics and Gynecology
Abstract
Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for early stage and locally advanced uterine cancer. For patients with early stage disease, minimizing toxicity, while preserving outstanding cure rates remains the major goal. For patients with locally advanced endometrial cancer optimal combined regimens are being defined. Risk stratification based on molecular traits is under development and may aid refine the current risk prediction model and permit personalized approaches for women with endometrial cancer.
Å°¿öµå
Adjuvant therapy, Early stage, Endometrial cancer, Locally advanced, Risk stratification
KMID :
1137020140250020136
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)